H epatocellular carcinoma (HCC) is the second-leading cause of cancer mortality worldwide, accounting for an estimated 788,000 deaths in 2015. (1, 2) Incidence in the United States has nearly tripled since 1975. (3) Additionally, the surge in nonalcoholic fatty liver disease in the United States, which is associated with the early development of liver cancer even in the absence of cirrhosis, threatens to further increase the incidence of HCC. (3) (4) (5) Despite advances in screening protocols, higher-resolution imaging, and improvements in oncologic and surgical HCC care, overall prognosis remains poor. In the United States, overall 5-year survival is 12% and median survival from the time of diagnosis for untreated disease is only 3.9 months. (6) Even when patients undergo potentially curative treatment with resection or transplantation, 5-year overall survival ranges from 21% to 78%. (7) Care for these patients is complex because HCC commonly develops in the setting of chronic liver disease, and the degree of hepatic decompensation directly impacts therapeutic options and the actual treatment a patient is eligible to receive. Current cancer therapies, delivered either in isolation or combination, include systemic chemotherapeutics, radiation, catheter-based therapies (i.e., bland or chemo-embolization and Yttrium-90), ablation, surgical resection, or orthotopic liver transplantation (OLT). (7) Patients with HCC, in particular those being considered for OLT, will frequently require management by a number of different specialties and treatment with multiple modalities to preserve or improve their potential for either resection or OLT. Because multiple medical specialties are typically involved in a given patient's cancer therapy and/ or medical management of their chronic liver disease, it follows that care for the patient with HCC is best delivered in a multidisciplinary fashion. (8) Multidisciplinary care has been associated with earlier stage of tumor presentation, decreased time interval to treatment, and improved median survival for patients with HCC. (9) Although the relative efficacy of specific therapeutic modalities for managing patients with HCC has been previously described, patient-level comparisons are subject to notable selection bias. (7) The impact of treating hospital characteristics, such as the number and type of therapeutic modalities offered, and the effect of hospital-specific resources on outcomes have not been well studied. A better understanding of the impact of these health care structural factors is vital in delivering highvalue care to patients with HCC through quality initiatives that are predicated on selective referral to regional centers. The purpose of this analysis was to describe the types of hospitals (based on the highest level of interventional services provided) treating patients with HCC, to characterize where these patients receive cancer care, and to examine the association between the type of treating hospital and overall survival. Our hypothesis is that patient outcomes are better at centers offering the full spectrum of HCC treatments, but a large proportion of patients do not receive care at such hospitals.
Patients and Methods

Data
This was a retrospective cohort study of patients with HCC in the National Cancer Data Base (NCDB).
The NCDB is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. It is a prospectively maintained, hospital-based cancer registry containing information on >70% of incident malignancies diagnosed in the United States annually at >1,500 CoCaccredited centers. It is a robust data source that has been extensively used to conduct oncologic health services research. This study was approved by the Baylor College of Medicine Institutional Review Board and the Michael E. DeBakey VA Medical Center Research & Development Committee.
StUDy CoHoRt
Within the NCDB, we identified 84,768 patients with HCC aged 18-70 years who were diagnosed from 2004 through 2012. Sequential exclusions were then made for diagnosis of additional previous or subsequent malignancy (n = 8,583), histology codes inconsistent with the HCC (n = 8,565), patients who were not diagnosed and treated at the reporting facility (n = 9,445), those who did not survive beyond 1 month after diagnosis (n = 7,565), and those for whom receipt of surgical treatment was unknown (n = 229). Patients not treated at the reporting facility were excluded to improve the ascertainment of all therapies. The final cohort included 50,381 patients with HCC.
VaRIaBleS
The main variable of interest was the type of treating hospital, which was categorized based on the highest level of interventional service provided during the study period. Specifically, hospitals were categorized into the following strata: (1) Type I (Nonsurgical-did not perform an ablation, resection, or transplants on any patients during the study period, but could have treated patients with either chemotherapy and/or radiation); (2) Type II (Ablation-could have provided similar treatments as Nonsurgical hospitals, but also treated patients with ablation); (3) Type III (Resectioncould have provided similar treatments as Nonsurgical and Ablation hospitals, but also treated patients with resection); (4) Type IV (Transplant-could have provided similar treatments as Nonsurgical, Ablation, and Resection hospitals, but also treated patients with transplant). Patients were separately categorized based on the type of treatment received as having undergone no treatment, chemotherapy and/or radiation, ablation, resection, or OLT. The data do not specifically identify the use of transarterial chemo-embolization or Yttrium-90; however, based on the manner data are coded, these patients are likely included among those categorized as having been treated with chemotherapy and/or radiation. This approach allowed patients to be identified based on treatment received and type of treating hospital (e.g., received ablation at a Type IV hospital).
StatIStICal aNalySIS
Distributions of categorical and continuous variables were evaluated with standard descriptive statistics. A nonparametric test for trend was applied to evaluate proportional changes at the patient-and hospital levels over time. The main outcome of interest was overall survival. The Kaplan-Meier method and the log-rank test were used to compare unadjusted survival. To explore the association between the type of treating hospital and risk of death, multivariable Cox shared frailty modeling (assuming a gamma distribution) was applied. Frailty modeling was selected to account for similarity in care and outcomes of patients clustered within a hospital. The hazard ratio estimates presented are intended to represent the patient-level effect of receiving care at a given type of treating hospital. Model covariates were selected in a nonparsimonious fashion and included age, sex, race, income, education, type of insurance, rurality, patient comorbidity, type of cancer program (i.e., academic, comprehensive, or community), and geographic region. Annual average HCC volume was also evaluated, and hospitals were stratified into quartiles. But only Type III and IV hospitals were in the two highest-volume quartiles. The assumption of proportional hazards was evaluated graphically. Overall and stage-specific modeling was performed. Stage was based on American Joint Committee on Cancer (AJCC) clinical stage, which is abstracted and reported prior to the receipt of any treatment. Clinical staging was chosen because this would be used in determining treatment options and because pathologic stage would not be available for patients treated nonsurgically.
Given the observational nature of this study and the association between cirrhosis and HCC, an important consideration was addressing the issue of confounding by indication because NCDB does not provide information on the severity of each patient's underlying liver disease. As such, we used three approaches to address this potential source of bias. First, all models only compared survival among patients who received the same type of treatment. Second, we conducted analyses in a stage-stratified fashion to better control for the extent of disease. Third, in designing this study, we elected to primarily focus on the effect of the type of hospital where a patient was treated rather than the type of treatment each patient received. Using this hospital-level approach may help to mitigate some of the effect of unmeasured confounders. (10) To address the issue of selection bias, we performed two additional sensitivity analyses: (1) Patients who received palliative treatment were excluded (n = 3,015), and (2) a landmark approach (of survival at least 6 months after diagnosis) was applied to our overall Cox model (n = 35,278). (11) A P value of <0.05 was considered statistically significant for all analyses. STATA version 14.0 (StataCorp, College Station, TX) was used to perform all analyses.
Results
Of 50,381 patients with HCC, 32,808 (65%) received care in a Type IV hospital, 13,118 (26%) in a Type III hospital, 1,410 (3%) in a Type II hospital, and 3,045 (6%) in a Type I hospital (Table 1) . Conversely, most hospitals in this series were Type I (539, 45.1%), followed by Type III (414, 34.6%), Type IV (138, 11.6%), and Type II (104, 8,7%). Although a higher portion of patients treated at Type IV centers had private insurance (46.6% versus 32.3%-36.2% in other types), there was a low rate of uninsured patients treated at all centers (1.3%-2.2%). Proportionately fewer patients resided in high-income areas for Type I centers (18.5% versus 20.8%-25.7%), whereas patients treated at Type IV hospitals tended to reside in areas with higher education (17.3% versus 12.5%-12.8%). Patients treated at Type IV or III hospitals more Among the 1,195 hospitals, there was no significant change in the proportion of hospitals in each category over time. An increasing proportion of patients were treated in Type IV hospitals over the study period (61.9% to 66.3%; trend test, P < 0.001).
Correspondingly, fewer patients were treated at Type I (7.0% to 5.4%; trend test, P < 0.001) and Type II hospitals (3.6% to 2.3%; trend test, P < 0.001). There was no change in the proportion of patients treated in Type III centers (27.5% to 26%; trend test, P = 0.06). With regard to types of treatment patients received, Fig. 1 presents the proportional use of each type of treatment stratified by the type of treating hospital. Proportional use of each treatment modality over time stratified by the type of treating hospital is presented in Fig. 2 
FIg. 2.
Proportional use of (A) no treatment, (B) chemotherapy and/or radiation, (C) locoregional therapy, and (D) resection and transplant stratified by type of treating hospital. In (D), the asterisk indicates proportion of OLT cases performed at Type IV hospitals over time.
and Type IV hospitals (trend test, P < 0.001), as did OLT (trend test, P < 0.001). Fig. 3 compares overall, unadjusted 5-year survival between types of hospital by treatment modality. Survival for untreated patients at Type IV hospitals (13.1%) was higher relative to all other hospital types (Type I-5.7%, Type II-7.0%, Type III-7.4%; log-rank, P < 0.001). Similar findings were noted for patients treated with chemotherapy and/or radiation (Type I-3.6%, Type II-4.6%, Type III-7.7%, Type IV-18.1%; log-rank, P < 0.001), ablation (Type II-13.6%, Type III-23.6%, Type IV-33.3%; logrank, P < 0.001), and resection (Type III-39.1%, Type IV-48.4%; log-rank, P < 0.001). For patients treated with transplant, 5-year survival was 75.1%. When patients were evaluated in a stage-stratified fashion (Table 2) , the findings were similar across all types of treatment modalities.
After adjusting for relevant clinical and demographic factors ( 
Discussion
Despite improved patient selection and treatment efficacy, a considerable number of patients with HCC in the United States do not receive potentially curative therapy. (12) The care of patients with HCC is often complicated by the severity of patients' coexisting, underlying liver disease. Providers with little experience managing such medically complex patients may be uncertain how best to provide oncologic care. Patients themselves may be unaware of the benefits of specific treatment modalities and, as such, may elect to receive whatever care is available at facilities close to their home. Although our study was not able to delineate the reasons for the disparity in outcome across different types of hospitals, our work does support several important conclusions. First, although two thirds of patients with HCC are treated in Type IV centers, this proportion has only modestly increased over time. Second, there is a clear survival advantage, regardless of the type of treatment received, associated with receiving care at hospitals that offer a broader complement of available HCC treatment modalities. Finally, the association between risk of death and the type of treating hospital demonstrates a dose-response relationship and is robust across the various types of treatment and stages of disease.
Simply increasing the number of patients treated may improve overall outcomes for HCC. (13) However, the location where patients are treated also plays an important role. Dalton-Fitzgerald et al. demonstrated that primary care providers deliver 60% of HCC monitoring for patients with cirrhosis, but only 15% of providers in a large urban hospital system practiced the Adjusted for age, sex, race, type of insurance, income, education, rurality, comorbidity, type of hospital (i.e., academic, community, etc.), and hospital region.
recommended biannual screening. (14) Also, considerable variation in referral patterns, time to referral, and specific consultation teams exists across the country. (15) Even within a single large academic institution, Stacy et al. found no uniform pattern of referral for evaluation and treatment of patients newly diagnosed with HCC. (16) Patient-level factors impacting timeliness of referral as well as access to potentially curative therapy for HCC include age, disease stage, geographic area, and the underlying causes of cirrhosis-patients with ongoing substance abuse are not candidates for OLT and therefore may not be referred for evaluation at Type IV centers. (15, 16) Other factors including insurance coverage, social support networks, race, and ethnicity also impact both the type of hospital in which patients are treated and the outcome following HCC diagnosis. (17) (18) (19) An important finding is the dose-response relationship between an increasing complement of interventional services offered by the treating hospital and improved patient outcomes across all therapeutic modalities and stages of disease. Undoubtedly, the potential causes of this survival benefit are multifactorial. This benefit may be due to differences in patient disease progression between groups of hospitals. Those centers offering the greatest number of clinical options may indeed see patients at an earlier stage where the chance of cure remains. Clearly, this may influence overall survival and cannot be assessed given the limitations of our dataset. Hospitals with a greater number and a higher complexity of therapeutic options likely treat a higher volume of patients with each treatment modality. Increased patient volume has been associated with improved outcomes for both radio frequency ablation and surgical resection in patients with HCC. (20, 21) Further, all transplant centers are required to have multidisciplinary medical support, (22) and most hospitals that offer major hepatic resection would be expected to have a number of these resources available as well.
An important topic in ongoing debate regarding U.S. health care reform is which hospitals should offer complex surgical care. Initiatives like "Take the Volume Pledge" aim to regionalize the care of patients with specific surgical problems to centers meeting established volume thresholds. (23) Although there are presently a number of potential concerns and no consensus regarding the value of national implementation of such an initiative, there may be certain diseases, such as HCC, for which the complexity of medical decision making and services required to provide optimal oncologic care may merit consideration within this type of model. (24) Given that one third of patients with HCC did not receive care at facilities offering the full spectrum of available therapies, future work is clearly needed to understand the feasibility, potential benefits, and costs associated with of this type of national policy.
The survival advantage observed across stages of disease and treatment modality may also be due to improved patient selection and triage to appropriate treatment strategy. Nathan et al. demonstrated that surgeons from different disciplines chose different treatment strategies when presented with similar clinical variables for patients with HCC, likely due to perceived differences in the significance of identical clinical variables by the individual surgeon. (25) In addition, the availability of liver transplant services near a surgeon's practice location influenced their clinical decision making even if his/her skill set did not include transplant. (26) By comparison, clinical factors that influence HCC medical decision making for gastroenterologists and hepatologists demonstrate increased consensus relative to surgeons. (27) The potential benefit for the patient with HCC treated in a multidisciplinary environment is the collaboration of these diverse perspectives in the formulation of an ultimate decision for therapy. As an example, multidisciplinary teams for HCC have been shown to increase patient referrals, the number of patients evaluated with earlier-stage disease, the use of curative therapies, and the use of multimodality therapies and to improve both survival and follow-up. (28) There are important limitations to consider when interpreting our findings. NCDB lacks information regarding the severity of underlying liver disease. As such, our findings could have been influenced by unmeasured selection bias, including the fact that only patients who were potential transplant candidates, regardless of treatment received, were selectively referred to Type IV hospitals. However, we believe that focusing on the effect of the treating hospital, comparing patients who received similar treatments, performing stage-stratified analyses to better adjust for the extent of each patient's disease, and the robustness of our study findings in additional sensitivity analyses likely mitigated this bias to the extent possible when using national cancer registry data. Although AJCC TNM staging data are provided in NCDB, this staging system is not commonly used in the assessment and clinical decision making for patients with HCC. Nonetheless, it did allow us to quantify the extent of each patient's disease. NCDB does not provide information regarding the intent of treatment or on sequential treatments-specifically, whether patients treated with chemotherapy or ablation were intended to be bridged to transplantation or whether patients who were transplanted were first treated with ablation. Therefore, an intentto-treat analysis is not possible using NCDB. Data regarding the availability and number of specialty physicians and services in a given hospital are not provided. Additionally, NCDB data do not provide information on how many hospitals were involved in an episode of cancer care or which aspects of care were provided at which hospitals. To address this limitation, we excluded patients not diagnosed and treated at the same facility. The NCDB only contains data from CoC-accredited hospitals, which may not broadly generalize to other hospitals in the general community. (29, 30) Finally, information on disease recurrence is not provided.
In conclusion, across all treatment modalities and stages of disease, patients with HCC have a lower risk of death when receiving care at hospitals that offer all treatment modalities. Although the majority of patients are treated at these types of hospitals, nearly one third of patients with HCC in the United States are not provided the opportunity to receive the full spectrum of multidisciplinary care. Further work is needed to identify institutional structural factors or care processes that could be implemented at hospitals that are unable to offer all available treatment modalities. Given an ongoing focus on quality and value in oncologic care in the United States, our data can be used to inform health policy initiatives pertaining to the regionalization of HCC cancer care.
